Nancy E. Kohl

Overview

Best Publications

• Active human immunodeficiency virus protease is required for viral infectivity.

  Nancy E. Kohl;Emilio A. Emini;William A. Schleif;Lenora J. Davis

  1939
  Citations

• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  NE Kohl;SD Mosser;SJ deSolms;EA Giuliani

  853
  Citations

• Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

  N E Kohl;C A Omer;M W Conner;N J Anthony

  705
  Citations

• Differential expression of myc family genes during murine development

  Kathryn A. Zimmerman;George D. Yancopoulos;Robert G. Collum;Russell K. Smith

  698
  Citations

• Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

  Jackson B. Gibbs;Allen Oliff;Nancy E. Kohl

  687
  Citations

• A Peptidomimetic Inhibitor of Farnesyl:Protein Transferase Blocks the Anchorage-dependent and -independent Growth of Human Tumor Cell Lines

  Laura Sepp-Lorenzino;Zhenping Ma;Elaine Rands;Nancy E. Kohl

  549
  Citations

• Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.

  N E Kohl;F R Wilson;S D Mosser;E Giuliani

  440
  Citations

• Mediator kinase inhibition further activates super-enhancer-associated genes in AML

  Henry E. Pelish;Brian B. Liau;Ioana I. Nitulescu;Anupong Tangpeerachaikul

  414
  Citations

• Induction of Apoptosis by an Inhibitor of the Mitotic Kinesin KSP Requires Both Activation of the Spindle Assembly Checkpoint and Mitotic Slippage

  Weikang Tao;Victoria J. South;Yun Zhang;Joseph P. Davide

  402
  Citations

• Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

  David A. Reardon;Prafulla C. Gokhale;Sarah R. Klein;Keith L. Ligon

  401
  Citations

• Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.

  J. B. Gibbs;D. L. Pompliano;S. D. Mosser;E. Rands

  400
  Citations

• Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival

  Bart Lutterbach;Qinwen Zeng;Lenora J. Davis;Harold Hatch

  377
  Citations

• First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

  Margit Hagel;Chandra Miduturu;Michael Sheets;Nooreen Rubin

  359
  Citations

• Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

  Robert B. Lobell;Charles A. Omer;Marc T. Abrams;Hema G. Bhimnathwala

  339
  Citations

• Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

  Mark M. Moasser;Laura Sepp-Lorenzino;Nancy E. Kohl;Allen Oliff

  269
  Citations

• Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

  G C Prendergast;J P Davide;S J deSolms;E A Giuliani

  263
  Citations

• A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

  Rebecca E. Barrington;Mark A. Subler;Elaine Rands;Charles A. Omer

  225
  Citations

• N-myc can cooperate with ras to transform normal cells in culture.

  George D. Yancopoulos;Perry D. Nisen;Abeba Tesfaye;Nancy E. Kohl

  221
  Citations

• Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.

  Huw D. Lewis;Matthew Leveridge;Peter R. Strack;Christine D. Haldon

  218
  Citations

• First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

  Richard D. Kim;Debashis Sarker;Tim Meyer;Thomas Yau

  212
  Citations